Flindr Therapeutics is a pre-clinical precision oncology therapeutics company developing targeted cancer drugs using its ImmunoGram Drug Discovery Engine. The ImmunoGram engine reverse-translates clinical heterogeneity in tumor- and host-specific factors into lab-based biological models to screen and select key drug targets. Its lead program is a first-in-class small-molecule inhibitor of RNF31 (HOIP) that has shown promising preclinical activity in ovarian cancer and B-cell lymphoma models and for which biomarkers have been identified to aid patient selection. The company was spun out of the Netherlands Cancer Institute and the Oncode Institute in 2020 and was previously called Immagene; it is led by CEO Maarten Ligtenberg. Flindr raised €20M in a Series A financing to advance its programs. The company intends to use the funds to progress the lead program toward IND, develop a second program, and broaden its pipeline using the ImmunoGram Drug Discovery Engine.

Total raised

$21M

Funding rounds

1

Latest round

Series A

Latest activity

Apr 2024